About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 209735, 8 pages
http://dx.doi.org/10.1155/2013/209735
Clinical Study

Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

1Department of Ophthalmology, College of Medicine, Seoul National University Bundang Hospital, 166 Gumiro, Bundang-gu, Seongnam, Gyeonggi-do 463-707, Republic of Korea
2Department of Ophthalmology, Seoul National University-Seoul Metropolitan Government Boramae Medical Center, 20 Boramae-ro 5 gil, Dongjak-gu, Seoul 156-707, Republic of Korea

Received 20 May 2013; Accepted 20 July 2013

Academic Editor: Tatsuya Mimura

Copyright © 2013 Seong Joon Ahn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods. This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection. Results. At month 6, BCVA change from baseline was (mean ± standard deviation) logMAR in the PRN group and  logMAR in the 3 monthly initial dose group. Mean CRT changes were in the PRN group and μm in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group ( injections) than in the 3 monthly initial dose group ( injections; ). Conclusions. Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.